OncoREX

Cancer Array

CodeProduct Name
40050

Sengenics OncoREX p53 AxCESS Array Kit

40060Sengenics OncoREX p53 AxCESS Array Service
40060-48Sengenics OncoREX p53 AxCESS Array Service Package (48 Samples)
40060-96Sengenics OncoREX p53 AxCESS Array Service Package (96 Samples)
Order on Science Exchange

Product Highlights

Product Description

Contains over 100 correctly folded and functional wild type and mutant p53 spotted in duplicate. Screen up to 8 samples per slide. Patented KREX functional proteomics technology which utilises the BCCP folding marker for the production of correctly folded and functional proteins.

Specifications

Product Namexx
Product Name

Sengenics OncoREX p53 AxCESS Array

Platform

Sengenics' proprietary Streptavidin-coated hydrogel surface chemistry provides an aqueous environment, preserving native protein folding and function. Due to the binding of the biotinylated BCCP folding marker with Streptavidin, proteins are oriented consistently with a single attachment point and are also distal (50Å) to the surface further enhancing their capability to fully interact with target biomolecules. KREX proteins behave as if they are in free solution, with full capability to interact at high specificity with autoantibodies and antibodies

Number of arrays

8 arrays (8 samples) per slide

Services

Services include running of samples on the array using the Sengenics OncoREX  p53 protein array Standard Autoantibody Assay Wet Lab Protocol. Includes quality control and standard fold change analysis using the Sengenics Standard Bioinformatics Pipeline

Sample type

Human serum/plasma
*please contact us for requirements of other types of samples

Delivery Lead Time

(40050) 2 weeks
(40060) 4 weeks

System CompatibilityAny open-format microarray scanner
Storage conditionsStore for up to 12 months at -20°c
Shipping

Frozen shipment in dry ice

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389